Discover
LENZ
LENZ Therapeutics, Inc.
5.79
2 x 4.27
2 x 7.24
bid
ask
+
0.11
1.94%
2 @ 04:00 PM
5.80 +0.01 (0.17%)
| Ytd | -63.81% | |
| 1y | -81.30% |
5.57
day range
5.98
5.23
52 week range
50.40
| Open | 5.60 | Prev Close | 5.68 | Low | 5.57 | High | 5.98 | Mkt Cap | 181.54M |
| Vol | 523.99K | Avg Vol | 779.99K | EPS | -3.64 | P/E | N/A | Forward P/E | -13.35 |
| Beta | N/A | Short Ratio | 13.18 | Inst. Own | 99.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 7.61 | 200-d Avg | 18.66 | 1yr Est | 54.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-05 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-07-30 | 2025-06 | 0 | N/A | 0.05 | 8.62% |
| 2025-05-07 | 2025-03 | 0 | N/A | 0.02 | 3.64% |
| 2025-05-07 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-19 | 2024-12 | 0 | N/A | N/A | N/A |
| 2025-03-19 | 2024-12 | 0 | N/A | -0.04 | -9.52% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-10-20 | Raymond James | Upgrade | Outperform | Outperform |
| 2025-10-10 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2025-08-01 | Citigroup | Upgrade | Buy | Buy |
| 2025-08-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-07-31 | Citigroup | Upgrade | Buy | Buy |
| 2025-07-31 | Raymond James | Upgrade | Outperform | Outperform |
Profile
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-13 | CHEVALLARD DANIEL R | Chief Financial Officer | 3.19K | Purchase |
| 2024-05-12 | MCCOLLUM JAMES W | Director | 0.00 | Purchase |
| 2024-03-20 | ODRICH MARC | Officer | 99.60K | Stock Award(Grant) |
| 2025-04-08 | OLSSON SHAWN | Officer | 4.73K | Conversion of Exercise of derivative security |
| 2024-03-20 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2025-03-06 | SCHIMMELPENNINK EVERT B. | Chief Executive Officer | 49.20K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | RA Capital Management, L.P. | 4.18M | 131.13M | 14.65% |
| 2025-06-29 | Alpha Wave Global, LP | 3.61M | 113.35M | 12.66% |
| 2025-06-29 | Paradigm Biocapital Advisors LP | 1.72M | 53.88M | 6.02% |
| 2025-06-29 | Blackrock Inc. | 1.43M | 44.95M | 5.02% |
| 2025-06-29 | Vanguard Group Inc | 1.29M | 40.51M | 4.53% |
| 2025-06-29 | Adage Capital Partners GP L.L.C. | 1.12M | 35.23M | 3.94% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 811.48K | 25.46M | 2.85% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 ETF | 398.94K | 12.52M | 1.40% |
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 257.10K | 8.07M | 0.90% |
| 2025-07-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 178.82K | 5.61M | 0.63% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 Growth ETF | 141.03K | 4.43M | 0.49% |
| 2025-09-29 | iShares Trust-iShares Biotechnology ETF | 138.48K | 4.35M | 0.49% |
Dividend
| Dividend | Date |
|---|---|
| 1.03 | 2024-03-22 |
| 1.03 | 2024-03-15 |
Split
| Split | Date |
|---|---|
| 1 : 7 | 2024-03-22 |